Humasis Co. Ltd. (KOSDAQ:205470)

Market Cap	85.88B -52.3%
Revenue (ttm)	30.11B +18.5%
Net Income	-15.62B
EPS	-138.00
Shares Out	113.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	671,664
Average Volume	1,631,311
Open	727.00
Previous Close	727.00
Day's Range	725.00 - 767.00
52-Week Range	663.00 - 1,945.00
Beta	0.11
RSI	46.06
Earnings Date	May 15, 2026

About Humasis

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women’s health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the quali...

• Industry: Medical - Equipment & Services
• Sector: Healthcare
• Founded: 2000
• Employees: 69
• Stock Exchange: KOSDAQ
• Ticker Symbol: 205470

Financial Performance

In 2025, Humasis's revenue was 30.11 billion, an increase of 18.49% compared to the previous year's 25.41 billion. Losses were -15.62 billion, -48.69% less than in 2024.